Triple-Negative Breast Cancer (TNBC)

Triple-negative breast cancer (TNBC) is a breast cancer that is lacking three important biomarkers: estrogen receptors (ER-), progesterone receptors (PR-), and HER2 receptors (HER2-). A triple-negative status is an important diagnostic result as it determines that certain hormone therapies or therapies targeting HER2 receptors will be ineffective in treating the breast cancer. Triple negative breast cancer is characterized by cells that resemble basal cells, and is typically considered a more aggressive, higher-grade cancer than other types of breast cancers. While patients with TNBC (making up 10% to 20% of all patients with breast cancer) are poor candidates to receive hormone therapy, they can be treated with the following therapies:

  • Chemotherapy
  • Radiation therapy
  • Emerging therapies, such as PARP inhibitors